Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 96822
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96822
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96822
Table 1 Demographic and clinical characteristics
| Characteristic | DPYD testing, n = 149 | No DPYD testing, n = 151 | Total, n = 300 |
| Median age | 66 (84-33) | 65 (85-34) | 65 (85-33) |
| ECOG PS | |||
| 0 | 133 (89) | 143 (95) | 276 (92) |
| 1 | 16 (11) | 8 (5) | 24 (8) |
| Sex | |||
| Male | 79 (53) | 86 (57) | 165 (55) |
| Female | 70 (47) | 65 (43) | 135 (45) |
| Type of cancer | |||
| Colon | 80 (54) | 87 (58) | 167 (55.7) |
| Rectal | 32 (21) | 46 (30) | 78 (26) |
| Gastric | 29 (19) | 16 (11) | 45 (15) |
| Esophageal | 1 (1) | 0 (0) | 1 (0.3) |
| Anal | 7 (5) | 1 (1) | 8 (2.7) |
| Appendiceal | 0 (0) | 1 (1) | 1 (0.3) |
| Stage of disease | |||
| Localized | 104 (70) | 95 (63) | 199 (66.3) |
| Metastatic | 45 (30) | 56 (37) | 101 (33.7) |
| Type of treatment | |||
| Monotherapy | 23 (15) | 20 (13) | 43 (14) |
| Monotherapy + RT | 20 (13) | 34 (23) | 54 (18) |
| Doublet | 97 (65) | 88 (58) | 185 (61.7) |
| Triplet | 9 (6) | 9 (6) | 18 (6) |
- Citation: D'Amato M, Iengo G, Massa N, Carlomagno C. Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution. World J Gastrointest Oncol 2025; 17(1): 96822
- URL: https://www.wjgnet.com/1948-5204/full/v17/i1/96822.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i1.96822